In a mouse model of SCLC, combined treatment with anti-VEGF and anti-PDL1 targeted therapy provided improved treatment outcome compared with anti-PDL1 or anti-VEGF monotherapy [198]. The gene discussed is VEGFA; the disease is small cell lung carcinoma.